Abstract

BackgroundFor the majority of patients with multimorbidity, the prescription of multiple long-term medications (polypharmacy) is indicated. However, polypharmacy poses a risk of adverse drug events, drug interactions and excessive treatment burdens. To help general practitioners (GPs) conduct more comprehensive medication reviews for patients with multimorbidity, we developed the theoretically-informed MultimorbiditY COllaborative Medication Review And DEcision Making (MY COMRADE) implementation intervention. In this study, we assessed the feasibility and acceptability of MY COMRADE by GPs.MethodsA non-randomised feasibility study using a qualitative framework approach was conducted. General practices were recruited by purposively sampling from interested GPs attending continuing professional development meetings (CPD) in southwest Ireland. Participating practices were instructed on the MY COMRADE implementation intervention which has five components: (i) action planning; (ii) allocation of protected time; (iii) peer-supported medication review; (iv) use of a prescribing checklist and (v) self-incentives (allocation of CPD points). GPs in participating practices agreed to conduct medication reviews on multimorbid patients from their own caseload using the MY COMRADE approach. After completing these reviews, qualitative interviews were conducted to evaluate GPs’ experiences of the intervention and were analysed using the framework method.ResultsGPs from ten practices participated in the study. The GPs reported that MY COMRADE was an acceptable approach to implementing medication review in general practice, especially for complex patients with multimorbidity. Action plans for the medication reviews varied between practices, but all reviews led to recommendations for optimising medications and patient safety. Many GPs felt that using the MY COMRADE approach would ultimately lead to more efficient use of their time, but a minority felt that the time and cost implications of using two GPs to review medications would not be sustainable unless greater incentives were used.ConclusionsThis study demonstrates that MY COMRADE is an acceptable and feasible approach to supporting comprehensive medication reviews for patients with multimorbidity. These findings indicate that a large scale trial of the effectiveness of MY COMRADE is now required to fully evaluate its potential to change prescribing behaviour and improve downstream outcomes such as prescribing appropriateness and treatment burden.Trial registrationISRCTN registry: ISRCTN34837446.

Highlights

  • For the majority of patients with multimorbidity, the prescription of multiple long-term medications is indicated

  • We assessed feasibility by examining three key uncertainties: is MY MultimorbiditY COllaborative Medication Review And DEcision Making (COMRADE) acceptable to General practitioner (GP); is it adaptable by GPs working in different contexts and do recommendations for medication optimisation arise from the medication reviews

  • Is MY COMRADE acceptable to GPs? In all interviews, GPs reported positive experiences of the intervention. Many said it sounded acceptable at first hearing: Cost and sustainability For GPs, the biggest perceived cost of MY COMRADE was time

Read more

Summary

Introduction

For the majority of patients with multimorbidity, the prescription of multiple long-term medications (polypharmacy) is indicated. To help general practitioners (GPs) conduct more comprehensive medication reviews for patients with multimorbidity, we developed the theoretically-informed MultimorbiditY COllaborative Medication Review And DEcision Making (MY COMRADE) implementation intervention. Over 50% of patients with chronic disease have multimorbidity (multiple chronic diseases) [2], which can lead to challenges in the provision of clinical care foremost of which is the management of multiple medications [3]. Multimorbidity is associated with higher rates of potentially inappropriate prescribing and adverse drug effects [4]; it is recommended that patients with multimorbidity have their medications reviewed periodically [5]. Uncertainty about how to balance guideline adherence and minimising the negative effects of polypharmacy can deter primary care physicians or general practitioners (GPs) from actively reviewing medications for their multimorbid patients [6, 7]. Systematic reviews of the effects of these interventions have shown inconsistent results with only limited evidence to show that they reduce medication-related problems or lead to meaningful clinical improvements [9,10,11]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call